Automation Pro Says India Pharmas Need To Automate More
This article was originally published in PharmAsia News
The head of an automation industry group says increased competition from China should lead Indian drug makers to step up automation of their manufacturing processes. The president of the Automation Industry Association said Indian pharmaceuticals were modernizing in other ways as they expand to global markets, but automation still is not a priority. The AIA leader said automation could become the key factor in competition. The chairman of Pharmexcil said maintenance costs and lack of timely service discouraged changeover. (Click here for more
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?